Beximco Pharmaceuticals (STU:R2WA) Cyclically Adjusted Revenue per Share: €0.38 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:R2WA Beximco Pharmaceuticals PLC STU:R2WA
69 GF Score
Price €0.53
GF Value €0.57
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Beximco Pharmaceuticals Cyclically Adjusted Revenue per Share?

Beximco Pharmaceuticals STU:R2WA -0.94% 69 Cyclically Adjusted Revenue per Share is €0.38 as of Mar. 2026. GuruFocus rates STU:R2WA with a GF Score™ of 69/100 and a GF Value™ of €0.57 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Beximco Pharmaceuticals's adjusted revenue per share for the three months ended in Mar. 2026 was €0.215. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.38 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Beximco Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 14.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 15.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 16.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Beximco Pharmaceuticals was 17.80% per year. The lowest was 13.70% per year. And the median was 17.40% per year.

As of today (2026-08-03), Beximco Pharmaceuticals's current stock price is €0.525. Beximco Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €0.38. Beximco Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 1.38.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Beximco Pharmaceuticals was 6.04. The lowest was 0.98. And the median was 2.53.


Beximco Pharmaceuticals  (STU:R2WA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Beximco Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.525/0.38
=1.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Beximco Pharmaceuticals was 6.04. The lowest was 0.98. And the median was 2.53.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Beximco Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


Beximco Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Beximco Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beximco Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Beximco Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.24 0.24 0.16 0.24 0.38

Beximco Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.32 0.38 0.34 0.35 0.38

STU:R2WA vs ZTS, UTHR, VTRS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beximco Pharmaceuticals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Beximco Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


STU:R2WA
69GF Score
Beximco Pharmaceuticals PLC STU:R2WA
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beximco Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Beximco Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.215/330.2130*330.2130
=0.215

Current CPI (Mar. 2026) = 330.2130.

Beximco Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.000 241.018 0.000
201609 0.062 241.428 0.085
201612 0.061 241.432 0.083
201703 0.060 243.801 0.081
201706 0.064 244.955 0.086
201709 0.067 246.819 0.090
201712 0.069 246.524 0.092
201803 0.067 249.554 0.089
201806 0.077 251.989 0.101
201809 0.085 252.439 0.111
201812 0.090 251.233 0.118
201903 0.091 254.202 0.118
201906 0.094 256.143 0.121
201909 0.090 256.759 0.116
201912 0.098 256.974 0.126
202003 0.104 258.115 0.133
202006 0.103 257.797 0.132
202009 0.109 260.280 0.138
202012 0.118 260.474 0.150
202103 0.116 264.877 0.145
202106 0.122 271.696 0.148
202109 0.133 274.310 0.160
202112 0.134 278.802 0.159
202203 0.141 287.504 0.162
202206 0.138 296.311 0.154
202209 0.154 296.808 0.171
202212 0.156 296.797 0.174
202303 0.151 301.836 0.165
202306 0.158 305.109 0.171
202309 0.176 307.789 0.189
202312 0.172 306.746 0.185
202403 0.173 312.332 0.183
202406 0.179 314.175 0.188
202409 0.185 315.301 0.194
202412 0.194 315.605 0.203
202503 0.199 319.799 0.205
202506 0.197 322.561 0.202
202509 0.217 324.800 0.221
202512 0.221 324.054 0.225
202603 0.215 330.213 0.215

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €0.38 mean?
Beximco Pharmaceuticals (STU:R2WA) has a Cyclically Adjusted Revenue per Share of €0.38 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Beximco Pharmaceuticals and its competitors.
Is Beximco Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
Beximco Pharmaceuticals' current Cyclically Adjusted Revenue per Share is €0.38. Overall, Beximco Pharmaceuticals has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Beximco Pharmaceuticals' Cyclically Adjusted Revenue per Share of €0.38 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Beximco Pharmaceuticals and its competitors. Beximco Pharmaceuticals's current Cyclically Adjusted Revenue per Share is €0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Beximco Pharmaceuticals (STU:R2WA) is currently considered Fairly Valued. The stock's GF Value™ is €0.57, compared to a current price of €0.53 — trading 7.9% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €0.38. Beximco Pharmaceuticals' overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Beximco Pharmaceuticals (STU:R2WA), the current Cyclically Adjusted Revenue per Share is €0.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beximco Pharmaceuticals (STU:R2WA) Overvalued in 2026?

Based on GuruFocus' analysis, Beximco Pharmaceuticals stock appears to be undervalued. The current stock price of €0.53 is trading 7.9% below its estimated GF Value™ of €0.57. GuruFocus considers Beximco Pharmaceuticals to be Fairly Valued.

Key valuation signals for STU:R2WA:

  • Cyclically Adjusted Revenue per Share: €0.38
  • GF Value™: €0.57 vs. price of €0.53 (7.9% below fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the STU:R2WA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Beximco Pharmaceuticals Business Description

Other Exchanges BXP:UKBXPHARMA:Bangladesh
Address 19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
69GF Score

Get the complete analysis for STU:R2WA

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.53
Price
€0.57
GF Value